Rep. James French Hill discloses trade(s) in KD, PFE, SFL, SOLV
James French Hill (AR02) disclosed 4 transactions, traded Dec 31: 0 purchases and 4 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Dec 31 | KD | Kyndryl Holdings, Inc. | Sell | $1,001 - $15,000 | Self |
| Dec 31 | PFE | HILL 1998 TRUST Pfizer, Inc. | Sell | $100,001 - $250,000 | Self |
| Dec 31 | SFL | Sale of full position for tax loss purposes. SFL Corporation Ltd | Sell | $15,001 - $50,000 | Self |
| Dec 31 | SOLV | Sale of full position for tax loss purposes. Solventum Corporation | Sell | $15,001 - $50,000 | Self |
ORIGINAL FILING ↗ALL FILINGS BY JAMES FRENCH HILL →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. representative has filed a financial disclosure covering stock transactions in four companies spanning pharmaceuticals, shipping, and biotech. Congressional stock trading disclosures are public records that can signal insider positioning or serve as a transparency checkpoint for potential conflicts of interest. Markets monitor such filings for patterns that might indicate legislative intent or advance knowledge of policy shifts affecting those sectors.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Hon. James French HillSep 29, 2026View the original filing at the House Clerk ↗
How This Could Play Out
First assessed Sep 29
Resolved
LIKELYThis disclosure represents routine tax-loss harvesting by a congressional member and would likely have no material market impact, as such filings are procedurally expected and reflect personal portfolio management rather than material non-public information.
Status quo
LIKELYIf no subsequent scrutiny or controversy emerges around the timing or rationale for these sales, the disclosure would fade from public attention with negligible effect on the underlying securities or broader market sentiment.
Worsens
UNLIKELYShould investigative reporting or regulatory review suggest the trades were timed to exploit material non-public information or violated the STOCK Act, reputational damage to the member could intensify broader congressional trading scrutiny, though direct price pressure on the four securities would remain minimal.
SPONSORED
More on Congressional Stock Trading
- Rep. James A. Himes files a Periodic Transaction ReportOct 20
- Rep. Jonathan Jackson discloses trade(s) in DDOG, EL, GH, TYG, VSATOct 19
- Rep. Michael Rulli discloses trade(s) in GOOG, WSBCOct 19
- Attorneys for Ilhan Omar seek return of items taken during home searchOct 17
- Rep. Laurel Lee discloses trade(s) in BAC, NOKBFOct 16
- Rep. Scott H. Peters files a Periodic Transaction ReportOct 15
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.